139 related articles for article (PubMed ID: 31180305)
1. Prostate cancer genomics: comparing results from three molecular assays.
Alam S; Tortora J; Staff I; McLaughlin T; Wagner J
Can J Urol; 2019 Jun; 26(3):9758-9762. PubMed ID: 31180305
[TBL] [Abstract][Full Text] [Related]
2. Transcript analysis of commercial prostate cancer risk stratification panels in hard-to-predict grade group 2-4 prostate cancers.
Lehto TK; Stürenberg C; Malén A; Erickson AM; Koistinen H; Mills IG; Rannikko A; Mirtti T
Prostate; 2021 May; 81(7):368-376. PubMed ID: 33734461
[TBL] [Abstract][Full Text] [Related]
3. Intratumoral and Intertumoral Genomic Heterogeneity of Multifocal Localized Prostate Cancer Impacts Molecular Classifications and Genomic Prognosticators.
Wei L; Wang J; Lampert E; Schlanger S; DePriest AD; Hu Q; Gomez EC; Murakam M; Glenn ST; Conroy J; Morrison C; Azabdaftari G; Mohler JL; Liu S; Heemers HV
Eur Urol; 2017 Feb; 71(2):183-192. PubMed ID: 27451135
[TBL] [Abstract][Full Text] [Related]
4. Genomic testing for localized prostate cancer: where do we go from here?
Loeb S; Ross AE
Curr Opin Urol; 2017 Sep; 27(5):495-499. PubMed ID: 28661898
[TBL] [Abstract][Full Text] [Related]
5. Commercial Gene Expression Tests for Prostate Cancer Prognosis Provide Paradoxical Estimates of Race-Specific Risk.
Creed JH; Berglund AE; Rounbehler RJ; Awasthi S; Cleveland JL; Park JY; Yamoah K; Gerke TA
Cancer Epidemiol Biomarkers Prev; 2020 Jan; 29(1):246-253. PubMed ID: 31757784
[TBL] [Abstract][Full Text] [Related]
6. Which, when and why? Rational use of tissue-based molecular testing in localized prostate cancer.
Ross AE; D'Amico AV; Freedland SJ
Prostate Cancer Prostatic Dis; 2016 Mar; 19(1):1-6. PubMed ID: 26123120
[TBL] [Abstract][Full Text] [Related]
7. Genomic Scores are Independent of Disease Volume in Men with Favorable Risk Prostate Cancer: Implications for Choosing Men for Active Surveillance.
Nyame YA; Grimberg DC; Greene DJ; Gupta K; Kartha GK; Berglund R; Gong M; Stephenson AJ; Magi-Galluzzi C; Klein EA
J Urol; 2018 Feb; 199(2):438-444. PubMed ID: 28941920
[TBL] [Abstract][Full Text] [Related]
8. Transcriptomic heterogeneity in multifocal prostate cancer.
Salami SS; Hovelson DH; Kaplan JB; Mathieu R; Udager AM; Curci NE; Lee M; Plouffe KR; de la Vega LL; Susani M; Rioux-Leclercq N; Spratt DE; Morgan TM; Davenport MS; Chinnaiyan AM; Cyrta J; Rubin MA; Shariat SF; Tomlins SA; Palapattu GS
JCI Insight; 2018 Nov; 3(21):. PubMed ID: 30385730
[TBL] [Abstract][Full Text] [Related]
9. Incorporation of tissue-based genomic biomarkers into localized prostate cancer clinics.
Moschini M; Spahn M; Mattei A; Cheville J; Karnes RJ
BMC Med; 2016 Apr; 14():67. PubMed ID: 27044421
[TBL] [Abstract][Full Text] [Related]
10. Genomic tests to guide prostate cancer management following diagnosis.
Colicchia M; Morlacco A; Cheville JC; Karnes RJ
Expert Rev Mol Diagn; 2017 Apr; 17(4):367-377. PubMed ID: 28277880
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of New Tests and Interventions for Prostate Cancer Management: A Systematic Review.
Olleik G; Kassouf W; Aprikian A; Hu J; Vanhuyse M; Cury F; Peacock S; Bonnevier E; Palenius E; Dragomir A
J Natl Compr Canc Netw; 2018 Nov; 16(11):1340-1351. PubMed ID: 30442734
[No Abstract] [Full Text] [Related]
12. Genomic Predictors of Outcome in Prostate Cancer.
Boström PJ; Bjartell AS; Catto JW; Eggener SE; Lilja H; Loeb S; Schalken J; Schlomm T; Cooperberg MR
Eur Urol; 2015 Dec; 68(6):1033-44. PubMed ID: 25913390
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Role of RNA Expression Molecular Biomarkers in Prostate and Bladder Cancers.
Ahmed ME; Todenhöfer T; Karnes RJ; Seiler R
Eur Urol Focus; 2022 May; 8(3):663-666. PubMed ID: 35843864
[TBL] [Abstract][Full Text] [Related]
14. Genomic Validation of 3-Tiered Clinical Subclassification of High-Risk Prostate Cancer.
Muralidhar V; Zhang J; Wang Q; Mahal BA; Butler SS; Spratt DE; Davicioni E; Sartor O; Feng FY; Mouw KW; Nguyen PL
Int J Radiat Oncol Biol Phys; 2019 Nov; 105(3):621-627. PubMed ID: 31271825
[TBL] [Abstract][Full Text] [Related]
15. Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline.
Eggener SE; Rumble RB; Armstrong AJ; Morgan TM; Crispino T; Cornford P; van der Kwast T; Grignon DJ; Rai AJ; Agarwal N; Klein EA; Den RB; Beltran H
J Clin Oncol; 2020 May; 38(13):1474-1494. PubMed ID: 31829902
[TBL] [Abstract][Full Text] [Related]
16. A 17-Gene Genomic Prostate Score as a Predictor of Adverse Pathology in Men on Active Surveillance.
Kornberg Z; Cooperberg MR; Cowan JE; Chan JM; Shinohara K; Simko JP; Tenggara I; Carroll PR
J Urol; 2019 Oct; 202(4):702-709. PubMed ID: 31026214
[TBL] [Abstract][Full Text] [Related]
17. Improving risk stratification among veterans diagnosed with prostate cancer: impact of the 17-gene prostate score assay.
Lynch JA; Rothney MP; Salup RR; Ercole CE; Mathur SC; Duchene DA; Basler JW; Hernandez J; Liss MA; Porter MP; Wright JL; Risk MC; Garzotto M; Efimova O; Barrett L; Berse B; Kemeter MJ; Febbo PG; Dash A
Am J Manag Care; 2018 Jan; 24(1 Suppl):S4-S10. PubMed ID: 29337486
[TBL] [Abstract][Full Text] [Related]
18. A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy.
Klein EA; Yousefi K; Haddad Z; Choeurng V; Buerki C; Stephenson AJ; Li J; Kattan MW; Magi-Galluzzi C; Davicioni E
Eur Urol; 2015 Apr; 67(4):778-86. PubMed ID: 25466945
[TBL] [Abstract][Full Text] [Related]
19. Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men.
Ross AE; Johnson MH; Yousefi K; Davicioni E; Netto GJ; Marchionni L; Fedor HL; Glavaris S; Choeurng V; Buerki C; Erho N; Lam LL; Humphreys EB; Faraj S; Bezerra SM; Han M; Partin AW; Trock BJ; Schaeffer EM
Eur Urol; 2016 Jan; 69(1):157-65. PubMed ID: 26058959
[TBL] [Abstract][Full Text] [Related]
20. Optimal Use of Tumor-Based Molecular Assays for Localized Prostate Cancer.
Lokeshwar SD; Syed JS; Segal D; Rahman SN; Sprenkle PC
Curr Oncol Rep; 2022 Feb; 24(2):249-256. PubMed ID: 35080739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]